Infertility accounts for 1.2% of pharmaceutical revenue – 06/13/2023 – Panel SA

Infertility has become a vitamin business in Brazil. The country currently represents 1.7% of global sales of the main laboratories and should increase to 4.2% in seven years.

A report by IVF Brazil, a consultancy specializing in assisted reproduction, shows that, worldwide, revenues from the sale of infertility drugs should rise from the current US$ 35.5 billion to US$ 50.1 billion in 2030.

The expectation is that sales in the country reach US$ 2.2 billion by then. Today, they move US$ 500 million, according to IVF.

Abbott, Bayer, Novartis, Merck, Pfizer, Sanofi, among others, sell drugs to try to combat the problems caused by the increase in hormonal disorders in the population of all age groups.

The WHO (World Health Organization) states that, at the moment, one in six people in the world suffer from infertility.

Infertility drugs are formulated to regulate hormone levels — such as stimulating ovulation or improving sperm production and quality

“Changes in lifestyle, the postponement of motherhood due to women’s professional careers and environmental issues are factors that are increasing the incidence of infertility in Brazil and driving the growth of the fertility medication industry”, says Fernando Prado, director of Neo Vita, clinic specialized in assisted reproduction.

With Diego Felix

PRESENT LINK: Did you like this text? Subscriber can release five free hits of any link per day. Just click the blue F below.